[Clinico-metabolic and anti-ischemic effects of angiotensin converting enzyme inhibitor lisinopril and its role in the process of left ventricular remodeling in patients with diabetic heart].
Clinico-metabolic and anti-ischemic effects of lisinopril and its influence on processes of left ventricular remodeling were studied on 64 patients with ischemic heart disease and stable class II-III effort angina combined with type 2 diabetes mellitus; 30 patients received standard therapy, 34--standard therapy plus lisinopril (5 mg/day). Investigation included Holter ECG monitoring, echocardiography, assessment of carbohydrate and lipid profile at baseline, in 1 and 3 months. Lisinopril exerted anti-ischemic effect, improved systolic and diastolic cardiac function, facilitated regression of left ventricular hypertrophy, and favorably affected carbohydrate and lipid metabolism at the background of body mass decrease. Lisinopril was well tolerated by patients.
Chilikina
N S
NS
Khasaev
A Sh
ASh
Abusueva
Z S
ZS
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000453:epidemiology*; D015716:Electrocardiography, Ambulatory / Q000379:methods; D005260:Female; D006801:Humans; D017706:Lisinopril / Q000494:pharmacology* / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000453:epidemiology* / Q000503:physiopathology; D012720:Severity of Illness Index; D020257:Ventricular Remodeling / Q000187:drug effects*
D000806:Angiotensin-Converting Enzyme Inhibitors; D001786:Blood Glucose; D017706:Lisinopril